ACCOLATE

Compare ACCOLATE  to:
Compare
Compare

Generic Name for ACCOLATE

Zafirlukast 10mg, 20mg; tabs.

Legal Classification:

Rx

Pharmacological Class for ACCOLATE

Leukotriene receptor antagonist.

Manufacturer of ACCOLATE

AstraZeneca Pharmaceuticals

Indications for ACCOLATE

Prophylaxis and chronic treatment of asthma.

Adult dose for ACCOLATE

Take 1 hour before or 2 hours after meals. 20mg twice daily.

Children's dosing for ACCOLATE

Take 1 hour before or 2 hours after meals. <5 years: not recommended. 5–11years: 10mg twice daily.

Warnings/Precautions for ACCOLATE

Not for primary treatment of acute attack. Discontinue if clinical symptoms of liver dysfunction occur; do not resume if confirmed by lab results. Caution when withdrawing from oral steroids. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for ACCOLATE

Potentiates warfarin (monitor PT and adjust warfarin dose). Caution with drugs metabolized by CYP2C9 (eg, tolbutamide, phenytoin, carbamazepine) or CYP3A4 (eg, dihydropyridine calcium channel blockers, cyclosporine, cisapride). Zafirlukast plasma levels reduced by erythromycin, theophylline. Zafirlukast plasma levels increased by aspirin. May increase theophylline levels.

Adverse Reactions for ACCOLATE

Headache, infection, GI upset, pain, fever; neuropsychiatric events (eg, insomnia, depression); rarely, hepatic dysfunction (esp. in females), agranulocytosis.

How is ACCOLATE supplied?

Tabs—60

Related Disease:

Asthma~antiasthmatics

Related Resources

FDA warns of stolen Advair Diskus product

July 19, 2010

The FDA has warned healthcare professionals and consumers not to use certain Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhalers stolen from a distribution warehouse in 2009 which have been found recently in some pharmacies.

Glassia approved for treating alpha 1 antitrypsin deficiency

July 06, 2010

Kamada announced that the FDA has approved Glassia (alpha1-proteinase inhibitor liquid) for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (AATD).

Dulera approved for the treatment of asthma

June 24, 2010

Merck announced that the FDA has approved Dulera (mometasone furoate and formoterol fumarate dihydrate) inhalation aerosol for the treatment of asthma in patients ≥12 years of age.

Phase 2b study of Aerovant for the treatment of eosinophilic asthma

June 08, 2010

Aerovance Inc. announced top-line results from its Phase 2b trial demonstrating that Aerovant (pitrakinra) is effective in a pre-defined subset of patients with eosinophilic asthma.

AeroChamber Plus Flow-Vu anti-static valved holding chamber available

June 04, 2010

Forest Pharmaceuticals and Lupin Pharmaceuticals have made available the AeroChamber Plus Flow-Vu anti-static valved holding chamber for use with metered dose inhalers (MDI).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions